CA-DIVERSIFIED-NANO
28.9.2018 14:52:06 CEST | Business Wire | Press release
Diversified Nano Solutions Corp launches revolutionary smartINK™ solutions to deliver the next generation of functional security printing to brand owners in any industry, institutions and individuals.
For the first time functional content printing and total security are delivered simultaneously and cost effectively by integrating copy-proof, unique and customer-specific smartQR™ biomarkers (watch video ) with the whole spectrum of digital inks.
Breakthrough smartINK ™ provides print and instant product identity and location tracking, at unbelievably low cost, on-the-spot, anywhere, anytime, by anyone.
Counterfeiting and illicit trade are pervasive in nearly every industry sector, harming consumers and brand owners, while costing the global economy over 1 trillion dollars annually.
Preservation of product and information integrity is increasingly important as sophisticated counterfeiting efforts easily defeat existing anti-counterfeit technologies.
smartINK™ makes it fun and easy to verify item integrity while establishing trust and defending item value. The smartINK™ solution scales easily, so individual brand owners and large enterprises alike can grow market share and successfully eliminate illicit trade and counterfeiting. Unbelievably low implementation costs enable fast payback and rapid deployment of secure mobile authentication and tracking worldwide.
As an expansion beyond digital print, DNSC is powering INKcrypt® smartQR™ available at www.goinkcrypt.com . FDA-compliant INKcrypt® smartQR™ enables tagging and marking of any physical object with traces of custom biomarkers using a variety of methods – including spray, brush, roll, flexo, offset and more.
Contact https://inkcryptink.com/ContactUs.aspx for details and to coordinate implementation of your smartINK™ and INKcrypt® smartQR™ solution.
smartINK™ solutions are compatible with inkjet platforms offered by Canon®, Screen®, Epson®, Ricoh®, HP®, FujiFilm®, Xerox®, Kyocera®, Konica Minolta® and more. Visit booth 829 at PRINT 18 September 30-October 2, 2018, in Chicago.
About DNSC
Diversified Nano Solutions Corporation (DNSC) , based in San Diego, California, specializes in developing, manufacturing and marketing high-performance inkjet inks and revolutionary, industry-unique smartINK™ solutions. Utilizing customer-specific INKcrypt® xDNA biomarker technology, smartINK™ provides total product & document security, proof of identity and worldwide tracking, anytime anywhere, at incredibly low cost. smartINK™ combines INKcrypt® xDNA™ biomarkers, the power of the internet and DNSC’s extensive product line of inks including CMYK , MICR (Magnetic Ink Character Recognition), invisible UV fluorescent / IR absorbing , spot and custom formulations .
Accessories and Security
DNSC supports its ink offerings with accessories to facilitate and aid x-nano™ ink use and smartINK™ solutions. These include specialty substrates, smartQR™ biomarker authentication testers, UV display lights, INKVERSE ™ “Infinite Ink Infuser” – a revolutionary and cost-effective way to adopt and deliver digital inks to existing and new inkjet systems via a continuous delivery ink supply system, and TransChrome ™ – an invisible color image generator to transform visible CMYK into invisible UV fluorescent red, green, blue, and white (RGBW) output, and more.
DNSC is presenting smartINK™ solutions, INKcrypt® smartQR™ and its line of black & color, magnetic, invisible, special effect, and security inks for the world’s leading inkjet print systems in the desktop, commercial and industrial inkjet space.
Visit us at booth 829 and discover the future of digital ink: functional, secure, trackable, differentiating!
View source version on businesswire.com: https://www.businesswire.com/news/home/20180928005061/en/
Contact:
For more information: Diversified Nano Solutions Corporation Linda Meyers US Headquarters: +1.858.924.1005 EMEA: +41.41 874 08 50 info@diversifiednano.com www.diversifiednano.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom